Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study PMC

However, it is also important to be aware that even sub-hallucinogenic doses of these substances can produce unwanted and unpleasant side effects. Another problem is that researchers do not yet know the possible long-term effects of this practice. These positive effects of microdosing were observed in all participants, regardless of whether they used psilocybin alone or a combination of either psilocybin with lion’s mane, or psilocybin, lion’s mane, and niacin. These assessments included self-report questionnaires to assess mood and symptoms of anxiety, depression, and stress. The researchers also assessed cognitive function and psychomotor ability, which refers to physical movements that require cognitive processing. For instance, a significant number of participants in previous placebo-controlled microdosing studies were able to recognize the effects of psilocybin during the study.

FDA: Recalled Microdosing Candies Linked to Reports of Illness Still on Shelves

The most widely suggested practice is taking one-tenth of a regular, recreational dose of a psychedelic once every 3 days (Fadiman, 2011; thethirdwave, 2018). There is some early research on using low doses of psychedelics (for review, see Passie, 2019); however, the exact dose along with the practiced dosing schedule people use today is not known. Microdosing LSD involves taking very small doses of LSD routinely, typically for an extended period of time. Proponents of microdosing LSD and anecdotal evidence suggest the practice may have health benefits, such as improving mood and cognition and treating mental health disorders and addiction. Interest in psychedelic mushrooms including Amanita muscaria has grown exponentially recently.

Microdosing Mushrooms: Dose, Benefits, Side Effects

Chocolate and cacao remain popular additions to psilocybin, whereas as adding Syrian rue (Peganum harmala), Lion’s Mane mushrooms (Hericium erinaceus) and/or niacin appear to be more recent phenomena21. Microdosing with psychedelics, the practice of taking a low dose of a psychedelic every couple of days, seems to be an increasing trend among science, technology, engineering, and mathematics professionals. Multiple anecdotal reports suggest performance enhancing effects; however, these positive reports may overshadow potential negative experiences. Findings show that the majority of the respondents indeed microdose to enhance performance.

Are there any risks?

1. In these studies, participants are administered one-tenth of a dose of psilocybin (a microdose) compared to what would cause a hallucinogenic effect.
2. Our results add to this series of double-blind placebo-controlled studies questioning the validity of anecdotal evidence for microdosing [4].
3. People with a history of psychotic disorders, such as bipolar disorder, schizophrenia, or other disorders, may also want to avoid microdosing, as the practice may be too stimulating.
4. Joseph Rootman has received research funding from Quantified Citizen Technologies who provided the data collection platform for this study.

As full-dose psychedelics appear to aide in the relief of severe, chronic psychiatric conditions (e.g. depression, anxiety, PTSD), milder mental health concerns may plausibly be treated by lower, recurring doses. This is especially worth considering if certain full-dose outcomes are found to rely on purely pharmacologic mechanisms rather than primarily on phenomenological experiences [27]. Owing to its origin as an underground practice, microdosing lacks standardized procedures that are accepted and replicated by the community [25]. The most frequently used compounds are LSD and psilocybin, the latter in the form of dried psychoactive mushrooms [7–9, 26]. Perhaps the most popular dosing schedule was proposed by James Fadiman, consisting of one dosing day followed by two days without dosing [17]. In the case of psilocybin mushrooms, microdoses are within the range of 0.1 g to 0.5 g of dried mushroom material [18], with 0.1 g considered roughly equivalent to ≈4.6 µg of LSD [26].

In a nutshell, the findings are looking a lot like the benefits of microdosing depend quite a lot on what folks are expecting it to do. Generally though, it seems many folks are microdosing around 0.1 grams (100 milligrams) to avoid that come-up feeling and any other distracting effects. In fact, in this dose range, many of the survey participants reported their concentration being increased rather than impaired, comparing the feeling to a strong cup of coffee.

“I was that kid who hated school, and microdosing small amounts of psilocybin helped me enjoy learning and stay morning-focused,” Dawn said. “Shrooms,” also known as magic mushrooms, are a popular hallucinogenic drug that has been used recreationally for centuries across the globe. And in recent years, some research has shown potential promise that, when taken in very tiny doses—also called “microdosing”—they might help treat major depression, anxiety and PTSD and https://sober-home.org/rebuilding-your-life-after-addiction/ possibly also enhance cognitive functioning and creativity. While scientific research on the benefits of microdosing mushrooms is still in its early stages, many people who have tried this practice report significant improvements in their mental health, creativity, and overall well-being. Some of the reported effects of microdosing mushrooms include improved mood, creativity, and productivity, as well as increased feelings of connection to oneself and others.

In order to determine if microdosing has the potential to improve mental well-being or treat certain mental disorders, there needs to be randomized controlled trials that compare the effects of microdosing to that of placebo. Of the research that has been done so far, most of these studies rely on respondents self-reporting their past experiences with microdosing. Such studies may not give a full depiction of the practice, since most of these participants already expect to have a good experience so their feedback may be biased.

In the review, most people engaged in microdosing psychedelics in periods lasting between 1 week and 2 years. The review also concluded that around half of the participants created their own protocol around microdosing. In a 2019 study involving an online survey of people’s experiences with microdosing, the most common dose was 10 micrograms (mcg).

When microdosing mushrooms, low doses are taken to help alleviate symptoms rather than to elicit a “high” or “trip.” The mushrooms most commonly used in microdosing contain a chemical called psilocybin, explains Davis. Whether you’re looking to tap into your creativity, improve mental health, or get more stuff done, microdosing mushrooms might be the ticket. The goal of microdosing is to experience the benefits of the psychedelic substance, without the intense and often overwhelming effects of a full dose. Whatever you decide to do, it can really help to keep a journal that keeps track of your dose, other substance intake (including caffeine and cannabis), mood, sleep, energy levels and any sort of effects you feel from the microdose. This can help you figure out your best protocol and dose and to decide if microdosing is the right tool for you.

Indeed, each of the constructs described in this taxonomy should be directly tested in placebo-controlled trials. To mitigate these risks, Johnson et al. [31] proposed safety guidelines for use with full-dose psychedelic substances, which rely on managing participant inclusion and having a comfortable, guided clinical setting. As microdosing does not involve the intensity of experience present in full-dose research, challenging experiences may be less likely. One may, however, anticipate that less frequent, less intense versions of full-dose challenges could be present even at the very low doses used in microdosing (e.g. restlessness instead of insomnia, mild anxiety instead of fear, mild headaches).

As seen in Verywell, Healthline, Psych Central, Everyday Health, and Health.com, among others. It also means people consuming these substances cannot access a controlled, safe supply. The drug could be adulterated (mixed in) with substances of a lower quality or dangerous product. The potential benefits of microdosing may include improvements in mood, sleep, and eating habits, among others. Research on the benefits and effects are largely inconclusive, and many medical professionals are split on whether or not microdoses cause a placebo effect or recall bias (remembering events as they wanted them to be rather than what they were). It’s not totally necessary to follow either of these protocols too strictly, but they do seem to help some folks get out of ruts and improve their mood.

In total, 1116 of the respondents were either currently microdosing (79.5%) or microdosed in the past (20.5%). Lysergic acid diethylamide (10 mcg) and psilocybin (0.5 g) were the most commonly used psychedelics with a microdosing frequency between 2 and 4 times per week. The most reported negative effects were of psychological nature and occurred acutely while under the influence. Despite the potential, the therapeutic applications of psilocybin in microdoses has yet to be studied clinically.

In sum, the results of this study add to the current evidence on the beneficial effects of microdosing psilocybin on mental health and mood, including among individuals with mental health concerns. In recent years, there has been a resurgence of scientific and popular interest in the potential use of psychedelic drugs for the treatment of depression, anxiety, and post-traumatic stress. For instance, psilocybin, the active ingredient in magic mushrooms, has shown promise in the treatment of individuals with depression, anxiety, and substance use disorders. The present https://sober-home.org/ study aimed to investigate, by means of an online questionnaire, the history of psychedelic use among microdosers, the dose and schedule they use, the prevalence of microdosing in the work environment, their motivation to microdose, and the potential negative effects. The survey was not specifically advertised as a microdosing survey but rather a psychedelic survey in general. Detailed questions about motives to use were only presented for microdosing since the study was not set up to test differences in motivations for use of regular doses and microdoses.

That’s with psilocybin; it would be much harder to dose mushrooms themselves because they contain other compounds, he added. In the present study, we develop a codebook of microdosing benefits and challenges (MDBC) based on the qualitative reports of a real-world sample of 278 microdosers. A 2021 study published in the New England Journal of Medicine found that psilocybin therapy was just as effective as traditional antidepressant treatments for moderate to severe depression. Research on the mental health benefits of microdosing mushrooms is still in the early stages, and some of the findings have been mixed. While research is ongoing, some early studies have shown that the substances could be as effective as some traditional treatments for anxiety and depression. But experts say more research is needed on the subject to truly establish its mental health benefits.

A 2023 study showed significant reductions in depressive symptoms for participants who took psilocybin after 43 days. Davis points to another trial published in 2022 that showed lasting effectiveness, with participants reporting “greater well-being” when evaluated after one year. I’ve suffered with PTSD, bipolar disorder and anxiety for years and my doctor and my therapist both endorse microdosing for my situation.

The late Apple founder Steve Jobs even credits the substance as playing a major role in his life and achievements. There hasn’t been much research on microdosing, with only a handful of ongoing or completed clinical trials assessing microdoses of psilocybin. A trial from Argentina published in Translational Psychiatry found microdosing mushrooms may result in noticeable subjective effects and altered brain activity, but evidence of enhanced well-being, creativity, and cognitive function is lacking. The first and most parsimonious hypothesis that could explain the parallelism between benefits and challenges is that the effects cancel out and nothing replicable is happening. The presence of opposite outcomes with a net-zero effect is what might be expected in an inactive condition dominated by noise.

In high doses it can cause effects such as the following, says Jeffrey A. Lieberman MD, psychiatrist-in-chief at Columbia University Medical Center of the New York-Presbyterian Hospital and director of the New York State Psychiatric Institute. It’s important to remember that microdosing psilocybin is only legal in a handful of cities and states. “It is important to keep in mind that you are still using a controlled substance, which may lead to detrimental side effects if abused or improperly taken. Any plan to microdose for medical reasons should be performed in a controlled environment with licensed individuals,” says Lal.

We also found decreased EEG power in the theta band under psilocybin, which is consistent with the broadband spectral power reductions reported for higher doses. Additionally, unavailability of an Android OS version of the QC application at the time of study limited participation to those with access to Apple devices. Given this potential bias, our characterization of the therapeutic use of microdosing should be interpreted with caution pending replication from research that employs a more systematic recruitment approach. Research that employs a more comprehensive psychodiagnostic approach would also increase our confidence of the generalizability of the findings to clinical populations who may consider microdosing to treat mental health concerns. Moreover, the present study did not assess microdosing practices engaged in prior to study completion.

The largest genus of psilocybin mushrooms, by far, is Psilocybe, but there are also species of Panaeolus, Conocybe, Inocybe, Gymnopilus, and Pluteus that are psychoactive as well. For example, the Food and Drug Administration (FDA) recently warned about a product line containing a propriety blend of mushrooms intended for microdosing. At least 12 people became severely ill after using the product, with 10 of them being hospitalized. While these studies suggest microdosing may offer subtle, short-lived benefits, all authors emphasized the need for more high quality research done in a controlled setting over a longer period of time across larger participant groups. Some participants experienced jitteriness, headaches, or anxiety, but no serious side effects were reported. But sometimes you might unknowingly be taking more than what’s considered a microdose, especially if you’re using psychedelics without supervision or guidance from a medical expert, she adds.

Overall, 44% of people who responded perceived that their mental health was much better as a consequence of microdosing. People also reported other benefits and enjoyments of microdosing, such as the ability to control the dose and the general lack of side effects. As a study in the Journal of Psychopharmacology notes, a technical definition of a microdose would be a dose of a drug that is only 1% of the active dose. People should be aware that there may be some risks to microdosing, including the fact that the scheduling of these substances makes them illegal to possess. Microdosing involves taking a very small dose of some popular hallucinogenic substances. Proponents of microdosing believe that the practice benefits the mind, and research has recently started to explore this possibility.